MAPK1 and cancer: The observed S6K inhibition at a high pimasertib dose (> 0.32 μM) on day 1 (Figure 5D) agreed with our previous finding of mTOR upregulation via ERK-dependent transcription in KRAS-mutant cancer cells [21].